|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||179.55 - 179.95|
|52-week range||39.82 - 179.95|
|PE ratio (TTM)||-25.85|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||156.56|
Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma. Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma. It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA.
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!
Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire Kite Pharma, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.
Gilead Sciences, Inc. today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. , for all of the outstanding shares of common stock of Kite Pharma, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Dodgers Merger Sub, Inc. (“Purchaser”), for all of the outstanding shares of common stock of Kite Pharma, Inc. (Nasdaq: KITE) at a price of $180 per share, net to the seller in cash, without interest. Computershare Trust Company, N.A., the depositary for the tender offer, has advised Gilead that, as of one minute after 11:59 p.m., New York City time, on October 2, 2017, the initial expiration of the tender offer, approximately 38,324,617 shares were validly tendered and not withdrawn in the tender offer, representing approximately 66.20% of Kite’s currently outstanding shares (including 2,003,002 shares delivered through Notices of Guaranteed Delivery, representing approximately 3.46% of the shares outstanding).
When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017. On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to customary closing conditions.
Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. In a first for gene therapy in the United States, regulators approved Kymriah on Wednesday for patients up to 25 years of age who have relapsed or not been helped by previous treatment for B-cell acute lymphoblastic leukemia (ALL). While patient groups hailed the potent immunotherapy as a potential cancer game-changer, the Swiss drugmaker was also criticised for setting a price that places Kymriah among the most-expensive drugs ever.
U.S. regulators this week approved the first drug for a new type of cancer treatment, confirming a theme some stock pickers have found in biotech.
Jim Cramer explains why a report on Apple's September 12 product meeting ignited a larger trading theme than Hurricane Harvey's aftermath.
The euro has been gaining against the dollar despite ECB chief Mario Draghi making no comments about monetary policy at a key meeting of central bankers last week.
Gilead Sciences said that it was paying $11.9 billion to acquire Kite Pharma, a firm which could soon have the first cell therapies available to sufferers of certain types of cancers
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter.
Gilead Sciences on Monday agreed to buy Kite Pharma for about $11 billion in cash, Dow Jones reported, citing sources.
Jim Cramer flies through his take on callers' favorite stocks, including one interest-rate-bound play.
Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, today announced that patients in the European Union (EU) are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1 (ClinicalTrials.gov, NCT: 02348216). Kite is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL) at multiple EU medical centers.